durvalumabatezolizumabplatinum-etoposidetremelimumabextensive-stage small cell lung cancerextensive-stage small-cell lung cancerimmunotherapyfirst-line chemotherapyES-SCLC
…otherapy, 563 (87.4%) received atezolizumab; 61 (9.5%) received durvalumab. We found that the median OS was 9 months vs 7.2 months (p <0.0…